EPiC-HFT
This clinical trial will investigate if home High-Flow Therapy (HFT) improves 12-month admission-free survival (time to readmission or death) following a severe exacerbation of COPD requiring hospitalisation. This is an area of unmet need, given the demonstrable limitations to current interventions which are costly, have extensive side-effects, limited availability and variable efficacy. If this this clinical trial demonstrates clinical and cost effectiveness of HFT, this technology could be rapidly incorporated into routine NHS clinical practice.
Open sites:
- GSTT
- Glasgow
- Leeds
- Hywel Dda
- Liverpool
- Royal Free
- Nottingham
- North Tyneside
- University of Leicester
- University Hospitals Birmingham
Recruitment to 09/08/2024: 72/502
Download the EPiC-HFT fact sheet (pdf, English)
Aims
To identify whether home HFT in addition to usual medical care improves 12-month admission-free survival following hospitalisation with a non-hypercapnic exacerbation of COPD.
Trials Design
This is a multi-centre randomised controlled trial in which patients hospitalised with COPD exacerbation are randomised to receive home HFT and usual care or usual care alone with a 12-month follow-up period.
Investigators
Professor of Respiratory and Citical Care Medicine
Clinical Lead Lane Fox Service
Chair in Medical Statistics and Clinical Trials
Affiliations
Funding
Funding Body: ResMed
Amount: £1,129,968
Period: March 2023 - February 2027